Hemolytic-uremic syndrome future or investigational therapies: Difference between revisions
Created page with "__NOTOC__ {{HUS}} {{CMG}} ==Overview== == Future or Investigational Therapies == :*ASA and dipyridamole not effective alone, ? benefit when added to plasma exchange :..." |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{HUS}} | {{HUS}} | ||
{{CMG}} | {{CMG}}, {{S.G.}} | ||
==Overview== | ==Overview== | ||
== Future or Investigational Therapies == | == Future or Investigational Therapies == | ||
Revision as of 13:46, 23 August 2018
|
Hemolytic-uremic syndrome Microchapters |
|
Differentiating Hemolytic-uremic syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hemolytic-uremic syndrome future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Hemolytic-uremic syndrome future or investigational therapies |
|
FDA on Hemolytic-uremic syndrome future or investigational therapies |
|
CDC on Hemolytic-uremic syndrome future or investigational therapies |
|
Hemolytic-uremic syndrome future or investigational therapies in the news |
|
Blogs on Hemolytic-uremic syndrome future or investigational therapies |
|
Risk calculators and risk factors for Hemolytic-uremic syndrome future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Sogand Goudarzi, MD [2]
Overview
Future or Investigational Therapies
- ASA and dipyridamole not effective alone, ? benefit when added to plasma exchange
- In poorly responsive or resistant disease, INCREASE PLASMA EXCHANGE
- Then consider:
- prednisone (1 mg/kg per day)
- methylprednisolone (125 mg IV bid)
- Vincristine
- IVIG